((beta AND blocker) OR (atenolol) OR (propranolol) OR (timolol) OR (metoprolol)) AND ((platelet AND... Page 1 of 4

SCITUS for scientific information only



About Us

Newsroom

Advisory Board

Submit Web Site

Help

Contact Us

Basic Search

Advanced Search Search Preferences

			((beta AND blocker) OR (atenolol) OR (propranolol) OF Search							
			✓ Journal sources	Preferred Web sources	✓ Oth	er Web source	s Exact phrase			
	Sea	rched for::	:All of the words:((beta AND blocker) OR (atenolol) OR (propranolol) OR (timolol) OR (metoprolol)) AND ((platelet							
		Found::	:6,040 total <u>3,156</u>	journal results 2,360 pr	eferred v	veb results	524 other web resu	<u>lts</u>		
		Sort by::	:relevance <u>date</u>							
			ecked results	Email checked resul	lts	Export ch	ecked results	Refine your search using these keywords		
	1.	Oct 2000	ers in acute myocard	ial infarction [67K]				found in the results: adhesive		
				rin , angiotensinenzyi blockers inthose with						
		withouttr	eated with propran	olol metoprolol, or at	enolol :	show figure		alkylene		
		more hits for similar resu		nu.edu.cn/uptodate/cor	onary%	20heart%20	di]	anti-infective agents		
	2			s (pindolol, atenolol, tim	olol and	metanrolol)	on aggregation	anti-ulcer agents		
Ш	۷.	and arachic	<u>lonic acid</u>				on aggregation	beta blockers		
		Srivastava INFLUEN	n , K.C. , <i>Prostaglandi</i> CE OE SOME RETA I	ns, Leukotrienes and Me BLOCKERS (PINDOLOL,	dicine, S	Sep 1987 LOL TIMO	OL AND	<u>biodegradable</u>		
		METOPRO	LOL) ON AGGREGAT	TON ANDThe effects of	of four b	eta -adrenoc	eptor	coronary		
				. Atenolol and metopr ological aggregation. Timolol of				delivery device		
		effects on p	latelet aggregation	. On thepotent vasodi	lator an	d inhibitor	of platelet	<u>hydrochloride</u>		
			ndevoted to the er journal article av a	fects of propranolol . As		=	et	<u>hypertension</u>		
			51 results from Scien	2 30.1	enceu	irect		<u>migraine</u>		
		similar resu		,000 W 000				<u>myocardial</u>		
	3.		on Practice Guidelin	es (Committee on Mana	gement	of Acute [PD	F-433K]	<u>osmotic</u>		
		Jun 1998 1373 As ı	oirin and Other Plat	elet-Active Drugs137	3 Mecha	nism of Actio	on of	polymer composition		
		Aspirin1	374 Aspirin in Prev	ention of Thrombotic Co	mplicati	ons		<u>semipermeable</u>		
		similar resu		c.org/clinical/guidelines/	miguiae	.parj		Or refine using:		
\Box	4.		gy 1995 Exam 4 Qu	estion 16 [PDF-2MB]				All of the words		
ш		Oct 2000			na avida	co inhihita.	tranulounromino	HATTER AND THE PARTY OF THE PAR		
		a. Ampheta serotonin u	mine b. LSD-25 c. P ptake inhibitor who <u>om</u> [http://www.uci	ructure to the monoaming hencyclidineCorrect. Find ise side effects include a hs.uci.edu/som/class20	luoxetir nxiety a	ie (Prozac) is ind insomnia	a selective . CN 330. It	Refine		
	5.			RIZATION OF HIGH MO	LECULA	<u>R WEIGHT P</u>	OLY			
		(BACKGROU to a solution phosphoest polymers m Full text at view all 225	ong / MAO, Hai-Qu JND OF THE INVENT on polymerization pro er linkages, in particle ade by the vailable at patent of results from Pater	an / LEONG, Kam W., ION)(1. Field of the Invicess for making high metallar those that degrade office. For more in-dent Offices	vention) olecular in vivo	The present weight polyr into non-tox	t invention relates ners containing ic residues. The			
	_	similar resu		- LVOI 401 - 0111 45 - 111			0.5075003 ***			
	6.	SOLUTION TOLUENE	POLYMERIZATION O	F HIGH MOLECULAR WE	IGHT PO	<u>)LY(PHOSPH</u>	OESTERS) IN			

		1) OD (
((beta AND	blo	ocker) OR (atenolol) OR (propranolol) OR (timolol) OR (metoprolol)) AND ((platelet AND Page 2 of 4
		ZHAO, Zhong, EUROPEAN PATENT, Apr 2000 (BACKGROUND OF THE INVENTION)(1. Field of the Invention) The present invention relates to a solution polymerization process for making high molecular weight polymers containing phosphoester linkages, in particular those that degrade in vivo into non-toxic residues. The polymers made by the Full text available at patent office. For more in-depth searching go to LexisNexis view all 2255 results from Patent Offices similar results
	7.	Rate of heart failure and 1-year survival for older people receiving low-dose β-blocker therapy after myocardial Rochon, P.A. / Tu, J.V. / Anderson, G.M. / Gurwitz, J.H. / Clark, J.P. / Lau, P. / Szalai, J.P. / () / Naylor, C.D., The Lancet, Aug 2000doses of beta-blocker therapy beta-blocker Dose rangeStandard High Atenolol6 =100* Metoprolol7 =200* Propranolol9 =180* Timolol8 =20* Acebutololdrug use Aspirin 9916 (720.001 ACE inhibitor 6978 (51
		Published journal article available from ScienceDirect view all 2751 results from ScienceDirect
		similar results
	8.	BIODEGRADABLE POLYMERS CHAIN-EXTENDED BY PHOSPHATES, COMPOSITIONS, ARTICLES AND METHODS FOR MAKING AND USING THE SAME MAO, Hai-Quan / ZHAO, Zhong / ENGLISH, James P. / LEONG, Kam W., EUROPEAN PATENT, Jan 2000 (BACKGROUND OF THE INVENTION)(1. Field of the Invention) The present invention relates to biodegradable polymer compositions, in particular those containing both phosphate and ester linkages in the polymer backbone and that degrade in vivo into non-toxic residues. The polymers of the invention
		Full text available at patent office. For more in-depth searching go to LexisNexis view all 2255 results from Patent Offices
		similar results
	9.	BIODEGRADABLE TEREPHTHALATE POLYESTER-POLY(PHOSPHATE) POLYMERS, COMPOSITIONS, ARTICLES, AND METHODS FOR MAKING AND USING THE SAME MAO, Hai-quan / LEONG, Kam W. / DANG, Wenbin / LO, Hungnan / ZHAO, Zhong / NOWOTNIK, David P. / ENGLISH, James P., EUROPEAN PATENT, Jan 2000 (BACKGROUND OF THE INVENTION)(1. Field of the Invention) The present invention relates to biodegradable homopolymer and block copolymer compositions, in particular those containing both phosphate and terephthalate ester linkages in the polymer backbone, which degrade in vivo into non-toxic
		Full text available at patent office. For more in-depth searching go to LexisNexis view all 2255 results from Patent Offices
		similar results
	10.	Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases Houston, M.C. / Hodge, R., American Heart Journal, Aug 1988tapering of the beta blocker and coadministrationD. Guanfacine 2. Beta-adrenergic blockers A. Propranolol (Inderal) B. Metoprolol (Lopressor) C. Atenolol (Tenormin) D. Timolol(Blocadren) E. Pindololcoverting enzyme inhibitors 4. Calcium channel blockers 5. Ganglionic neuronCombination drugs A. Beta-adrenergic blockers
		Published journal article available from ScienceDirect
		view all 2751 results from ScienceDirect similar results
	11.	PYRIDOXAL ANALOGUES FOR VITAMIN B-6 DISORDERS HAQUE, Wasimul, PATENT COOPERATION TREATY APPLICATION, Sep 2000has been implicated in modulation of platelet aggregation; it is an inhibitor of certain phosphatase enzymes; andreperfusion injury, blood coagulation, platelet aggregation, and diseases that ariseexample, angiotensin converting enzyme inhibitor, an angiotensin 11 receptor antagonistreperfusion injury, blood coagulation, platelet aggregation, and diseases that arise
		Full text available at patent office. For more in-depth searching go to view all 2255 results from Patent Offices similar results
	12.	Meta - analysis of Multitreatment Studies [PDF-13K] Mar 2000for the Effect of Beta Blockers Factor Propranolol Timolol Nadolol Metoprolol Effect Standard ConfidenceLog-likelihood = 30.0742 Propranolol Timolol N a d o l o l + Metoprolol I I I I : I - 1 0 1 2 effectestimated effect sizes of four beta-blocker drugs comparedOuimet H, McCans J, et al. Aspirin, heparin, or both to treatTrial of heparin versus atenolol in prevention of myocardial [http://umg.umdnj.edu/smdm/pdf/18-01-037.pdf] similar results

((pera AIV		ocker) OR (atenolol) OR (propranolol) OR (timolol) OR (metoprolol)) AND ((platelet AND Page 3 of 4
. •] 13	BIODEGRADABLE TEREPHTHALATE POLYESTER-POLY(PHOSPHONATE) AND POLYESTER- POLY (PHOSPHITE) COMPOSITIONS, ARTICLES, AND METHODS OF USING THEM MAO, Hai-quan / LEONG, Kam W. / ZHAO, Zhong / DANG, Wenbin / ENGLISH, James P. / NOWOTNIK, David P., PATENT COOPERATION TREATY APPLICATION, Apr 2000 The invention comprises biodegradable terephthalate polymers comprising the recurring monomeric units shown in formula (I), wherein R is a divalent organic moiety; R' is hydrogen, an aliphatic, aromatic or heterocyclic residue; x is ≥ 1; and n is 3-7,500, Full text available at patent office. For more in-depth searching go to LexisNexis view all 2255 results from Patent Offices similar results
	14	Two-stage solution polymerization of high molecular weight poly(phosphoesters) Zhao, Zhong / Mao, Hai-quan / Leong, Kam W., UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT, Dec 1999examples of useful biologically active substances from the above categories include: (a) anti-neoplastics such as androgen inhibitors, antimetabolites, cytotoxic agents, and immunomodulators; (b) anti-tussives such as dextromethorphan, dextromethorphancholestryramine; (h) anti-arrhythmics such as N-acetylprocainamide; (i) antipyretics and analgesics such as acetaminophen, aspirin and ibuprofen; (j) appetite suppressants such as phenyl-propanolamine hydrochloride or caffeine; (k) expectorants such Full text available at patent office. For more in-depth searching go to LexisNexis view all 2255 results from Patent Offices
		similar results
] 15	Zhao, Zhong, UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT, Sep 1999examples of useful biologically active substances from the above categories include: (a) anti-neoplastics such as androgen inhibitors, antimetabolites, cytotoxic agents, and immunomodulators; (b) anti-tussives such as dextromethorphan, dextromethorphan hydrobromide Full text available at patent office. For more in-depth searching go to view all 2255 results from Patent Offices similar results
	16	Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same Mao, Hai-Quan / Leong, Kam W. / Zhao, Zhong / English, James P., UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT, Dec 2000 Biodegradable polymers are described comprising the recurring monomeric units shown in formula I or II: wherein X isO orNR', where R' is H or alkyl; L is a branched or straight chain aliphatic group having from 1-20 carbon atoms; M.sub.1 and Full text available at patent office. For more in-depth searching go to view all 2255 results from Patent Offices similar results
] 17	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same Mao, Hai-quan / Leong, Kam / Zhao, Zhong / Dang, Wenbin / English, James / Nowotnik, David, UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT, Nov 2000 A medical device is described comprising a biodegradable terephthalate copolymer comprising the recurring monomeric units shown in formula I below: ##STR1## wherein R is a divalent organic moiety; R' is an aliphatic, aromatic, or heterocyclic residue; x Full text available at patent office. For more in-depth searching go to LexisNexis view all 2255 results from Patent Offices similar results
	18	SOLUTION POLYMERIZATION OF HIGH MOLECULAR WEIGHT POLY(PHOSPHOESTERS) IN TOLUENE ZHAO, Zhong, PATENT COOPERATION TREATY APPLICATION, Jan 1999 A process for making a high molecular weight poly(phosphoester) comprising the recurring monomeric units of formula (I), wherein X is -O- or -NR"-, where R" is H or alkyl; L is a divalent organic moiety, with the proviso that L cannot have formula (II); Full text available at patent office. For more in-depth searching go to LexisNexistation of the proviso that L cannot have formula (II); Full text available at patent office. For more in-depth searching go to
2.	19	BIODEGRADABLE COMPOSITIONS COMPRISING POLY(CYCLOALIPHATIC PHOSPHOESTER) COMPOUNDS, ARTICLES, AND METHODS FOR USING THE SAME DANG, Wenbin / MAO, Hai-quan / SHIPANOVA-KADIYALA, Irina / LEONG, Kam W. / ZHAO, Zhong / ENGLISH, James P., PATENT COOPERATION TREATY APPLICATION, Nov 1998 Biodegradable, flowable or flexible polymer compositions are described comprising a polymer having the recurring monomeric units shown in formula (I), wherein: each of R and R' is

((beta AND blocker) OR (atenolol) OR (propranolol) OR (timolol) OR (metoprolol)) AND ((platelet AND... Page 4 of 4

independently straight or branched alkylene, either unsubstituted or ...

Full text available at patent office. For more in-depth searching go to
View all 2255 results from Patent Offices

similar results

20. <u>BIODEGRADABLE POLYMERS CHAIN-EXTENDED BY PHOSPHATES, COMPOSITIONS, ARTICLES AND METHODS FOR MAKING AND USING THE SAME</u>

MAO, Hai-Quan / ZHAO, Zhong / ENGLISH, James P. / LEONG, Kam W., PATENT COOPERATION TREATY APPLICATION, Oct 1998

Biodegradable polymers are described comprising the recurring monomeric units shown in formula (I) or (II) wherein X is -O- or -NR'-, where R' is H or alkyl; L is a branched or straight chain aliphatic group having from 1-20 carbon atoms; M 1 and M 2 are ...

Full text available at patent office. For more in-depth searching go to LexisNexisview all 2255 results from Patent Offices similar results

:::fast

Results Pages: [<< Prev] 1 <u>2</u> <u>3</u> <u>4</u> <u>5</u> <u>6</u> <u>7</u> <u>8</u> <u>9</u> <u>10</u> <u>11</u> <u>12</u> <u>13</u> <u>14</u> <u>15</u> <u>16</u> <u>17</u> <u>18</u> <u>19</u> <u>20</u> [Next >>]

back to top

<u>Downloads</u> | <u>Subscribe to News Updates</u> | <u>User Feedback</u> | <u>Advertising</u> <u>Tell A Friend</u> | <u>Terms Of Service</u> | <u>Privacy Policy</u> | <u>Legal</u>

Powered by FAST © Elsevier 2007